Subscribe to Updates
Get the latest creative news from FooBar about art, design and business.
Browsing: Pharma
As Gilead’s Trodelvy stumbles in first-line lung cancer, all eyes are on Merck, Arizona, and No. 1 rival
By healthadmin
The race to bring TROP2 antibody-drug conjugates (ADCs) to first-line non-small cell lung cancer (NSCLC)…
AstraZeneca employees’ LinkedIn activity has once again landed the drug company in hot water, with…
ADA: Lilly posts data for oral semaglutide topping as Foundayo accelerates toward second potential in diabetes
By healthadmin
With the green light already in place for obesity, Eli Lilly is moving forward with…
It’s a sign of the times that at this year’s American Diabetes Association (ADA) Scientific…
ADA: Novo’s Wegovy tablets reach new GLP-1 patients and reach impressive milestone of 3 million prescriptions
By healthadmin
For Novo Nordisk, the company’s long-awaited launch of Wigovy tablets earlier this year, the first…
The FDA has expanded the labeling of Pfizer’s subcutaneous hemophilia treatment Himpazi to include patients…
ADA: Amgen highlights benefits of Repatha and pitfalls of GLP-1 for improving cardiometabolic pedigree
By healthadmin
Amgen aims to become the industry’s top player in cardiometabolic risk reduction by the beginning…
Stalled pipelines and failed AI pilots create persistent hurdles in drug discovery. Explore 2026 biopharma trends, infrastructure strategies, manufacturing investments, and FDA regulatory shifts.
Explore key 2026 biopharma trends, AI integration in drug discovery, and strategic steps for regulatory success amid evolving FDA policies.
Takeda Pharmaceutical takes legal liability of $2.5 billion after receiving late payment judgment, and will be in the red in 2025
By healthadmin
A recent antitrust ruling will force Takeda to revise its financials for 2025, with the…